Quantum Si Inc【QSI】株式ニュース

Quantum-Si Announces First Customer Samples Tested on the Proteus™ Prototype SystemApril 8, 2026 9:15 AM
Business Wire
Sequencing Results Utilizing a Proteus Prototype System Exceeds Platinum® Pro

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule protein sequencing, today announced that the Company has completed the sequencing of multiple samples provided by an existing Platinum Pro customer on a Proteus prototype system.

The testing included sequencing the samples on both Platinum Pro and a Proteus prototype system. For Platinum Pro, the Company used the commercially available Version 3 Library Preparation Kit and Version 4 Sequencing Kit. For the Proteus prototype, the Company used the Version 3 Library Preparation Kit and a developmental sequencing kit that contains the latest amino acid recognizer set.

The sequencing results were consistent with the information that the Company shared at the November 2025 Investor and Analyst Day demonstrating that Proteus was far exceeding Platinum Pro performance across all relevant metrics. Specifically, the Proteus prototype and developmental sequencing kit demonstrated significantly improved amino acid coverage, longer read lengths, more peptides identified and greater sequencing output even when normalized for the difference in the number of nanowells on a Platinum Pro chip versus the Proteus KinetIQ™ array.

“We are very excited to have successfully completed the sequencing of our first customer samples on the Proteus prototype system,” said Jeff Hawkins, President and Chief Executive Officer of Quantum-Si. “Being able to demonstrate that the Proteus prototype system exceeds Platinum performance across all metrics on real world samples is an important milestone in the development of this new platform. We expect sequencing performance to continue to increase from here as we work to further optimize the Proteus system into our final commercial offering.”

Hawkins continued, “This is just one of many customers who have indicated interest in providing samples for sequencing on the Proteus prototype. We are working closely with our manufacturing partners to increase the rate of delivery of integrated Proteus systems to meet both internal R&D demand and provide additional capacity to be able to offer customer sample testing to the market through a formal pre-launch sample evaluation program. We look forward to providing more updates on this program on our next earnings call.”

About Quantum-Si Incorporated

Quantum-Si is transforming proteomics with a benchtop platform that brings single-molecule protein analysis to every lab, everywhere. The Company’s platform enables real-time kinetic-based detection and allows researchers to move beyond traditional, multistep workflows and directly access dynamic, functional protein insights with unparalleled resolution. By making protein analysis simpler, faster, and more informative, Quantum-Si is accelerating proteomic discoveries to improve the way we live. Learn more at quantum-si.com or follow us on LinkedIn or X.

Forward Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s expectations with respect to future performance and development and commercialization of products, services and applications, its anticipated cash runway, the anticipated timing of product launches and product capabilities (including Proteus), investor confidence in Quantum-Si and our strategic roadmap, and any financial guidance. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Many of these factors are outside the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the inability to maintain the listing of the Company’s Class A common stock on The Nasdaq Stock Market; the ability of the Company to grow and manage growth and retain its key employees; the Company’s ongoing leadership transitions and succession planning; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company’s product development and commercialization activities, including the use and benefit of artificial intelligence in these and other activities; the commercialization and adoption of the Company’s existing products and the success of any product the Company may offer in the future, including Proteus; the potential attributes and benefits of the Company’s commercialized Platinum protein sequencing instruments and kits and the Company’s other products (including Proteus) once commercialized; the Company’s ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company’s ability to identify, in-license or acquire additional technology; the Company’s ability to maintain its existing lease, license, manufacture and supply agreements; the Company’s ability to compete with other companies currently marketing or engaged in the development or commercialization of products and services that serve customers engaged in proteomic analysis, many of which have greater financial and marketing resources than the Company; the size and growth potential of the markets for the Company’s products and services, and its ability to serve those markets once commercialized, either alone or in partnership with others; the Company’s estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company’s financial performance; the Company's defense and initiation of litigation matters; and other risks and uncertainties described under “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and in the Company’s other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260408765544/en/
Investor and Media

Jeff Keyes

Chief Financial Officer

ir@quantum-si.com

Original: Quantum-Si Announces First Customer Samples Tested on the Proteus™ Prototype System

Quantum-Si Reports Fourth Quarter and Full Year 2025 Financial ResultsMarch 3, 2026 4:05 PM
Business Wire
Releases List Price of Proteus™ Platform

Reiterates Proteus Development Program On Track for Year End 2026 Launch

Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics technology company redefining protein analysis through single-molecule detection, today announced financial results for the fourth quarter and full year ended December 31, 2025.

Press Release Highlights

Reported fourth quarter revenue of $451,000

Reported on track development of the Proteus platform and related R&D programs to expand proteome coverage and enable broad PTM analysis capabilities

Announced list price for Proteus of $425,000

Announced 2026 Financial Guidance

“2025 was a year of significant progress as we continued to advance our technology through multiple new kit launches, expanding the installed base and consumable utilization of our first-generation Platinum Pro system, and delivered on our key strategic goal of demonstrating sequencing on our Proteus prototype system that exceeded our current technology across all key performance metrics,” said Jeff Hawkins, President and Chief Executive Officer of Quantum-Si. “Since our Investor & Analyst Day in November 2025, engagement from both existing and prospective customers around Proteus has developed nicely. Given the level of customer, prospective customer, and channel partner interest, we elected to release our Proteus list price a quarter earlier than originally planned, allowing our commercial team to more effectively work with customers to incorporate Proteus into their capital budgeting cycles. At a list price of $425,000, we believe Proteus is priced to capture the premium value of the platform and expected launch capabilities while also making the platform accessible to a larger number of potential customers than existing technologies.”

Hawkins continued, “As we move through 2026, we expect tempered near-term revenue based upon deliberate strategic choices. These include continuing to offer the placement program we initiated during 2025 and embedding upgrade credits into Platinum Pro units sold during 2026 to provide a clear path to Proteus for customers. While this approach moderates near-term revenue, we believe it positions Proteus for a stronger launch and supports long-term shareholder value creation.”

Fourth Quarter 2025 and Full Year 2025 Financial Results

For the fourth quarter of 2025, the Company recorded revenue of $0.5 million. Gross profit was $0.1 million resulting in a gross margin of 27%. For the full year ended December 31, 2025, the Company recorded revenue of $2.4 million, gross profit of $1.2 million, and gross margin of 47%. Gross margin is expected to be variable in the near term as the Company progresses through the initial stages of commercialization and as the timing and mix of product sales between instruments and consumable kits fluctuate.

Total operating expenses were $21.2 million in the fourth quarter of 2025, compared to $31.3 million in the same period of the prior year, and $117.3 million for the full year ended December 31, 2025, compared to $110.2 million in the prior year. Adjusted total operating expenses, a non-GAAP financial measure, were $18.3 million in the fourth quarter of 2025 compared to $26.7 million in same period of the prior year, and $86.3 million for the full year ended December 31, 2025, compared to $99.0 million in the prior year. Overall, adjusted operating expenses decreased year over year, reflecting continued cost discipline, streamlined research and development activities, and a more focused allocation of resources toward delivering the Proteus platform.

Net loss was $17.6 million in the fourth quarter of 2025, compared to a net loss of $33.1 million in the same period of the prior year, and $101.3 million for the full year ended December 31, 2025, compared to $101.0 million in the prior year. Adjusted EBITDA, a non-GAAP financial measure, was negative $17.0 million in the fourth quarter of 2025, compared to negative $25.1 million in the same period of the prior year, and negative $80.7 million for the full year ended December 31, 2025, compared to negative $92.8 million in the prior year. A reconciliation of adjusted total operating expenses and adjusted EBITDA to the most directly comparable GAAP measures is included in this press release.

Included in total operating expenses and net loss were one-time charges associated with legacy litigation matters that were reserved or settled during the year ended December 31, 2025, totaling $18.7 million.

As of December 31, 2025, the Company’s cash and cash equivalents and investments in marketable securities totaled $215.8 million.

2026 Financial Guidance

For the full year 2026, the Company provided the following financial guidance:

Revenue:

Approximately $1.0 million

Adjusted total operating expenses:

$98.0 million or less

Total cash usage:

$93.0 million or less

The Company expects 2026 revenue to be impacted by deliberate strategic actions taken in advance of the anticipated Proteus launch. These actions include embedding upgrade credits into Platinum Pro units sold in 2026 to provide customers with a clear path to Proteus, as well as customers choosing to delay purchasing decisions as they plan for the Proteus platform. As a result, 2026 is expected to represent a transition year as the Company prioritizes positioning Proteus for a successful commercial launch and long-term adoption. This revenue guidance reflects intentional tradeoffs designed to support market readiness and long-term platform adoption and is not indicative of underlying demand or the Company’s long-term growth opportunity.

Adjusted total operating expenses are expected to include all activities required to complete development and support of the commercial launch of the Proteus platform with its anticipated capabilities by the end of 2026. The Company expects to continue managing operating expenses with discipline while prioritizing investments directly tied to Proteus execution and launch readiness.

Total cash usage is expected to include operating expenses related to Proteus development, as well as modest inventory build and commercial readiness activities ahead of the anticipated Proteus launch.

The Company believes its cash, cash equivalents, and investments in marketable securities of $215.8 million as of December 31, 2025, will provide sufficient runway to execute on the Proteus launch and support operations into the second quarter of 2028.

Webcast and Conference Call Information

Quantum-Si will host a conference call to discuss its fourth quarter and full year 2025 financial results on Tuesday, March 3, 2026, at 4:30 p.m. Eastern Time. Individuals interested in listening to the conference call may do so by joining the live webcast in the Investors section of the Quantum-Si website under Events and Presentations. Alternatively, individuals can register here to receive a dial-in number and personalized PIN to participate in the call. An archived webcast of the event will be available for replay following the event.

About Quantum-Si Incorporated

Quantum-Si is transforming proteomics with a benchtop platform that brings single-molecule protein analysis to every lab, everywhere. The Company’s platform enables real-time kinetic-based detection and allows researchers to move beyond traditional, multistep workflows and directly access dynamic, functional protein insights with unparalleled resolution. By making protein analysis simpler, faster, and more informative, Quantum-Si is accelerating proteomic discoveries to improve the way we live. Learn more at quantum-si.com or follow us on LinkedIn or X.

Use of Non-GAAP Financial Measures

This press release presents the non-GAAP financial measures “adjusted total operating expenses” and “adjusted EBITDA.” The most directly comparable measures for these non-GAAP financial measures are total operating expenses and net loss. The Company has included below adjusted total operating expenses, which presents the Company’s total operating expenses after excluding stock-based compensation, net lease termination expense, legal settlement expense, net of insurance proceeds, restructuring costs and other non-recurring operating expenses. In addition, adjusted EBITDA further excludes interest, taxes, depreciation, amortization, dividend and interest income, changes in fair value of warrant liabilities and other income or expense.

A discussion of the reasons why management believes that the presentation of non-GAAP financial measures provides useful information to investors regarding the Company’s financial condition and results of operations is included as Exhibit 99.2 to the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on March 3, 2026.

Forward Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The actual results of the Company may differ from its expectations, estimates, and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company’s expectations with respect to future performance and development and commercialization of products and services, its anticipated cash runway, anticipated data and product launches, investor confidence in Quantum-Si and our strategic roadmap, and any financial guidance for 2026. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the inability to maintain the listing of the Company’s Class A common stock on The Nasdaq Stock Market; the ability of the Company to grow and manage growth profitably and retain its key employees; the Company’s ongoing leadership transitions; changes in applicable laws or regulations; the ability of the Company to raise financing in the future; the success, cost and timing of the Company’s product development and commercialization activities, including the use and benefit of artificial intelligence in these and other activities; the commercialization and adoption of the Company’s existing products and the success of any product the Company may offer in the future; the potential attributes and benefits of the Company’s commercialized Platinum® protein sequencing instruments and kits and the Company’s other products once commercialized; the Company’s ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product; the Company’s ability to identify, in-license or acquire additional technology; the Company’s ability to maintain its existing lease, license, manufacture and supply agreements; the Company’s ability to compete with other companies currently marketing or engaged in the development or commercialization of products and services that serve customers engaged in proteomic analysis, many of which have greater financial and marketing resources than the Company; the size and growth potential of the markets for the Company’s products and services, and its ability to serve those markets once commercialized, either alone or in partnership with others; the Company’s estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; the Company’s financial performance; and other risks and uncertainties described under “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and in the Company’s other filings with the SEC. The Company cautions that the foregoing list of factors is not exclusive. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.

QUANTUM-SI INCORPORATED

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share and par value amounts)

(unaudited)

December 31,

2025

December 31,

2024

Assets

Current assets:

Cash and cash equivalents

$

21,639

$

49,241

Marketable securities, current

141,271

160,362

Accounts receivable, net of allowance of $270 and $124, respectively

561

1,333

Legal settlement insurance receivable

4,638

—

Inventory

3,197

4,067

Prepaid expenses and other current assets

4,554

3,006

Total current assets

175,860

218,009

Marketable securities, non-current

52,855

—

Property and equipment, net

13,194

15,993

Operating lease right-of-use assets

3,464

13,061

Other assets

234

808

Total assets

$

245,607

$

247,871

Liabilities and Stockholders’ Equity

Current liabilities:

Accounts payable

$

1,623

$

1,931

Accrued payroll and payroll-related costs

5,903

5,331

Accrued contracted services

3,356

2,379

Accrued legal settlement liability

8,000

—

Accrued expenses and other current liabilities

1,505

4,848

Warrant liabilities, current

794

—

Current portion of operating lease liabilities

1,844

3,698

Total current liabilities

23,025

18,187

Warrant liabilities, non-current

—

4,995

Operating lease liabilities

2,322

9,250

Other long-term liabilities

34

19

Total liabilities

25,381

32,451

Stockholders’ equity:

Class A Common stock, $0.0001 par value; 600,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 196,431,273 and 146,953,271 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively.

20

16

Class B Common stock, $0.0001 par value; 27,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 19,937,500 shares issued and outstanding as of December 31, 2025 and December 31, 2024.

2

2

Additional paid-in capital

918,190

811,998

Accumulated other comprehensive (loss) income

(6

)

45

Accumulated deficit

(697,980

)

(596,641

)

Total stockholders’ equity

220,226

215,420

Total liabilities and stockholders’ equity

$

245,607

$

247,871

QUANTUM-SI INCORPORATED

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(in thousands, except per share amounts)

(unaudited)

Three months ended December 31,

Years ended December 31,

2025

2024

2025

2024

Revenue

Product

$

415

$

1,149

$

2,286

$

2,925

Service

36

43

150

133

Total revenue

451

1,192

2,436

3,058

Cost of revenue

Product

329

569

1,249

1,404

Service

—

13

34

54

Total cost of revenue

329

582

1,283

1,458

Gross profit

122

610

1,153

1,600

Operating expenses:

Research and development

10,946

16,988

53,759

59,641

Selling, general and administrative

10,270

14,299

44,754

50,535

Lease termination expense, net

—

—

13,577

—

Legal settlement expense, net of insurance proceeds

—

—

5,162

—

Total operating expenses

21,216

31,287

117,252

110,176

Loss from operations

(21,094

)

(30,677

)

(116,099

)

(108,576

)

Dividend income

155

152

697

1,728

Interest income

2,067

2,065

8,964

9,638

Change in fair value of warrant liabilities

279

(4,639

)

4,202

(3,722

)

Other income (expense), net

990

(9

)

955

(19

)

Loss before provision for income taxes

(17,603

)

(33,108

)

(101,281

)

(100,951

)

Provision for income taxes

(8

)

(13

)

(58

)

(56

)

Net loss

$

(17,611

)

$

(33,121

)

$

(101,339

)

$

(101,007

)

Net loss per common share attributable to common stockholders, basic and diluted

$

(0.08

)

$

(0.23

)

$

(0.51

)

$

(0.71

)

Weighted-average shares used to compute net loss per share attributable to common stockholders, basic and diluted

209,185

146,239

197,765

143,196

Other comprehensive (loss) gain:

Net unrealized (loss) gain on marketable securities, net of tax

$

(58

)

$

(93

)

$

(63

)

$

70

Foreign currency translation adjustment

(2

)

(15

)

12

(25

)

Total other comprehensive (loss) gain, net of tax

(60

)

(108

)

(51

)

45

Comprehensive loss

$

(17,671

)

$

(33,229

)

$

(101,390

)

$

(100,962

)

QUANTUM-SI INCORPORATED

RECONCILIATION OF U.S. GAAP TO NON-GAAP FINANCIAL MEASURES

(in thousands)

(unaudited)

Three months ended December 31,

Years ended December 31,

2025

2024

2025

2024

Net loss

$

(17,611

)

$

(33,121

)

$

(101,339

)

$

(101,007

)

Adjustments to reconcile to EBITDA:

Dividend income

(155

)

(152

)

(697

)

(1,728

)

Interest income

(2,067

)

(2,065

)

(8,964

)

(9,638

)

Depreciation and amortization

1,173

994

4,454

4,600

Provision for income taxes

8

13

58

56

EBITDA

(18,652

)

(34,331

)

(106,488

)

(107,717

)

Adjustments to reconcile to Adjusted EBITDA:

Change in fair value of warrant liabilities

(279

)

4,639

(4,202

)

3,722

Other (income) expense, net

(990

)

9

(955

)

19

Stock-based compensation

2,687

2,319

10,665

8,722

Lease termination expense, net

—

—

13,577

—

Legal settlement expense, net of insurance proceeds

—

—

5,162

—

Other non-recurring operating expenses

252

—

1,230

—

Restructuring costs

—

2,221

280

2,418

Adjusted EBITDA

$

(16,982

)

$

(25,143

)

$

(80,731

)

$

(92,836

)

Three months ended December 31,

Years ended December 31,

2025

2024

2025

2024

Total operating expenses

$

21,216

$

31,287

$

117,252

$

110,176

Adjustments to reconcile to Adjusted total operating expenses:

Stock-based compensation

(2,687

)

(2,319

)

(10,665

)

(8,722

)

Lease termination expense, net

—

—

(13,577

)

—

Legal settlement expense, net of insurance proceeds

—

—

(5,162

)

—

Other non-recurring operating expenses

(252

)

—

(1,230

)

—

Restructuring costs

—

(2,221

)

(280

)

(2,418

)

Adjusted total operating expenses

$

18,277

$

26,747

$

86,338

$

99,036

View source version on businesswire.com: https://www.businesswire.com/news/home/20260303534840/en/
Investor and Media:

Jeff Keyes

Chief Financial Officer

ir@quantum-si.com

Original: Quantum-Si Reports Fourth Quarter and Full Year 2025 Financial Results